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ABSTRACT 
Background: Despite advances in therapies to treat breast cancer, over 100,000 patients die 
in the UK of this disease per year, highlighting the need to develop effect predictive and 
prognostic markers for patients with primary operable ductal breast cancer.  Therefore, the 
aim of the present study was to examine the relationship between membranous, cytoplasmic 
and nuclear expression of focal adhesion kinase (phosphorylated at Y 397, Y 861 and Y 925), 
molecular subtypes, tumour microenvironment and survival in patients with primary operable 
ductal breast cancer. 
Methods: 474 patients presenting between 1995 and 1998 with primary operable ductal 
breast cancer were included in this study.  Using tissue microarrays expression of 
membranous, cytoplasmic and nuclear tumour cell phosphorylation of FAK at Y397, Y861 and 
Y925 was assessed, and associations with clinicopathological characteristics, tumour 
microenvironment and cancer-specific survival (CSS) were examined. 
Results: No significant association was observed for ph-FAK Y861 with survival at all sites.  
However, high expression of membranous ph-FAK Y397 was associated with increased 
tumour grade (P<0.001), molecular subtypes (P<0.001), increased tumour necrosis 
(P<0.001), high Klintrup–Mäkinen grade (P<0.001), increased CD138+ plasma cells 
(P=0.031), endocrine therapy (P=0.001) and poor cancer specific survival (P=0.040).  
Similarly, high expression of nuclear ph-FAK Y397 was associated with decreased age 
(P=0.042), increased CD138+ plasma cells (P=0.001) and poor cancer specific survival 
(P=0.003).  Furthermore, high expression of cytoplasmic ph-FAK Y925 was associated with 
decreased tumour grade (P<0.001), less involved lymph node (P=0.020), molecular subtypes 
(P<0.001), decreased tumour necrosis (P<0.001), low Klintrup–Mäkinen grade (P<0.001), 
decreased CD4+ T-cells (P=0.006), decreased CD138+ plasma cells (P=0.034), endocrine 
therapy (P<0.001), chemotherapy (P=0.048), and improved cancer specific survival 
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(P=0.044).  On multivariate analysis, high expression of nuclear ph-FAK Y397 was 
independently associated with reduced cancer specific survival (P=0.017). 
Conclusion: The results of the present study show that membranous and nuclear ph-FAK 
Y397 and cytoplasmic ph-FAK Y925 were associated with prognosis in patients with primary 
operable ductal breast cancer.  In addition, high expression of nuclear ph-FAK Y397 was an 
independent prognostic factor in patients with primary operable ductal breast cancer and 
could be incorporated into clinical practice.
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INTRODUCTION 
Breast cancer is a heterogeneous disease and is the most common cancer in females 
worldwide.  In the UK, breast cancer is the second most common cancer representing 30% of 
all female cancers.  Despite the routine use of hormone receptor status [1], TNM staging 
system [2], and the recent introduction of molecular subtypes to identify likely outcomes and 
plan treatment, it is clear such staging approaches are suboptimal and require refinement. 
Recently, there has been an increasing interest in studying the tumour 
microenvironment and how it affects disease outcome.  Indeed, it is clear that the interaction 
between the tumour and its microenvironment are crucial for long-term survival.  In breast 
cancer, many studies have highlighted the association between components of the tumour 
microenvironment and patient survival [3, 4, 5].  In particular, some phenotypic features such 
as the local inflammatory infiltrate and stromal infiltrate have recently been reported to have 
independent prognostic value in patients with primary operable ductal breast cancer [6, 7, 8].  
Therefore, there is now increasing interest in the signalling transduction pathways that may 
be important in regulating such important phenotypic features. 
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor protein tyrosine kinase that 
plays a critical role in cell motility and undergoes intracellular activation by multiple factors, 
such as Src Kinase, phospholipase and growth-factor-receptor-bound protein-7 [9].  In human 
cancers, increased tumour expression of FAK has been shown in several cancer types 
including lung, cervical and colon cancer when compared to normal tissue [10, 11, 12].  
Phosphorylation of FAK at Y397 although not a measure of full activation itself, is a surrogate 
measure of activation and is associated with enhanced tumour growth, migration, invasion, 
adhesion and spreading, as well as tumour angiogenesis through regulation of both cancer 
cells and their microenvironment [13, 14, 15].  In two studies of more than 1800 patients with 
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breast cancer, total FAK expression was significantly associated with neo-angiogenesis and 
reduced cancer specific survival [16; 17].  Indeed, it has been reported that nuclear FAK 
regulates the anti-tumour immune response [18].  Moreover, auto-phosphorylation of FAK at 
Y397 allows binding of Src Kinase or other substrates such as ERK and PI3K to promote 
tumorigenesis [15; 19].  Once auto-phosphorylated, phosphorylation of FAK Y861 can occur 
via Src [20] and phosphorylation of FAK Y925 can occur via ERK [21] to mediate distinct 
downstream effects. 
In the last decade, a number of studies have documented the role of total FAK in many 
types of cancer including breast cancer [10, 11, 12].  However, there is less information about 
the role of phosphorylated form at each site (membranous, cytoplasmic and nuclear).  
Therefore, it was of interest to examine in more detail expression of ph-FAK Y397 (auto-
phosphorylation) and ph-FAK Y861 (Src dependent phosphorylation) at different sites and 
highlight the relationship of each phosphorylation site individually with clinicopathological 
characteristic to provide novelty to our work. 
Therefore, the aim of the present study was to examine relationship between 
phosphorylated membrane, cytoplasmic and nuclear FAK at Y397 (ph-FAK Y397), Y861 (ph-
FAK Y861), and Y925 (ph-FAK Y925), molecular subtypes, the tumour microenvironment and 
cancer specific survival in patients with primary operable ductal breast cancer.
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PATIENTS AND METHODS 
Patient cohort 
Patients presenting with primary operable ductal breast cancer at Glasgow Royal and 
Western Infirmaries and Stobhill Hospital, in the West of Scotland, between 1995 and 1998 
that had formalin-fixed paraffin embedded blocks of the primary tumour available for 
evaluation were studied (n=474).  The tissue was obtained from the Glasgow Biorepository 
and was approved by the Research Ethics Committee of the West Glasgow University 
Hospitals NHS Trust (REC reference 07/s0704/61).  Individual patient consent was not 
required for this study. 
Clinical and pathological characteristics 
Clinicopathological data included age, tumour size, tumour grade, lymph node status, 
type of surgery, and type of adjuvant therapy (chemotherapy, hormonal therapy and/or 
radiotherapy) was retrieved from the routine reports.  Tumour grade was assigned according 
to Nottingham Grading System.  Specific information on DCIS and on the resection margin 
status in this patient cohort was not available.  ER and PR status were assessed on tissue 
microarrays (TMAs) using immunohistochemistry (IHC) and scored according to the 
American Society of Clinical Oncology and College of American Pathologists guidelines 
with cut-off value of 1% positive tumour nuclei [22].  HER-2 status were assessed visually 
using TMA sections as previously described i.e. a score 3+ is regarded as positive; 2+ is 
regarded as equivocal, leading to referral for HER-2 FISH; and 0 and 1+ are regarded as 
negative [23]. 
Proliferation index was assessed by Ki-67 IHC using established protocols in the 
Department of Pathology, Glasgow Royal Infirmary with appropriate positive and negative 
controls [24].  Blood (BVI) and lymph (LVI) vessel invasion were assessed, on 2.5 μm thick 
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sections, using IHC staining with the lymphatic endothelial marker D2-40 (SIG-3730, 
Covance, USA) diluted 1:100 and vascular endothelial marker Factor VIII (Leica, UK) 
diluted 1:100 as previously described [25].  Patients were routinely followed up after surgery.  
Date and cause of death was cross-checked with the cancer registration system and the 
Registrar General (Scotland).  Death records were complete until 31st of May 2013 and that 
served as the censor date.  Cancer-specific survival was measured from the date of primary 
surgery until the date of death from breast cancer. 
Assessment of the tumour microenvironment 
Full-section haematoxylin and eosin (H&E) slides taken at the deepest point of invasion 
were used to score local inflammatory infiltrate according to Klintrup Mäkinen (KM) grade 
as previously described [6].  Briefly, the inflammatory cell infiltrate at the invasive margin 
was classified as either low-grade (no increase or mild/patchy increase in inflammatory cells) 
or high-grade (prominent inflammatory reaction forming a band at the invasive margin, or 
florid cup-like infiltrate).  Individual immune cells type was assessed using IHC staining on 
TMA sections for helper and cytotoxic T-lymphocytes, macrophages and plasma cells using 
CD4+, CD8+, CD68+ and CD138+ staining as previously described [26].  Full-section H&E 
slides were also used to score the tumour stroma percentage (TSP) and tumour budding as 
previously reported [8; 27].  Briefly, a single field was examined for TSP and graded as either 
low (≤50%) or high (>50%) and 5 fields were examined for budding and the highest bud 
count per field was used. 
Immunohistochemistry 
Immunohistochemical expression of ph-FAK Y397, ph-FAK Y861 and ph-FAK Y925 
was carried out using previously constructed tissue microarrays as previously reported [23].  
TMAs contained 0.6-mm cores with three cores per patient and were sectioned at 2.5um 
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thickness.  TMA sections were dewaxed in histoclear before being rehydrated using graded 
alcohols.  Antigen retrieval for ph-FAK Y397, ph-FAK Y861 and ph-FAK Y925 was performed 
using Tris-EDETA buffer (pH 9) at 96oC for 20 minutes before cooling.  Endogenous 
peroxidase activity was blocked using 3% hydrogen peroxide for 15 minutes for ph-FAK 
Y397; 20 minutes for ph-FAK Y861 and 10 minutes for ph-FAK Y925.  Normal horse serum 
was applied for 60 minutes at 250C as a blocking solution.  TMA sections were then 
incubated for 60 minutes at 250C with primary antibody for ph-FAK Y397 (ab39967, Abcam,  
UK) and ph-FAK Y861 (44-626G, Invitrogen, UK) at a concentration of 1:200.  For ph-FAK 
Y925, TMA sections were incubated with primary antibody (PA5-21148, SAB, UK) overnight 
at 40C at a 1:6000 dilution.  Envision (Dako) secondary antibody was added for 30 minutes at 
room temperature.  Proteins were visualised using DAB substrate then counterstained in 
haematoxylin and blued with Scotts’ tap water before being dehydrated through a series of 
graded alcohols.  Cover slips were applied using distrene, plasticizer, xylene (DPX). 
Scoring method 
Stained TMA sections were scanned using a Hamamatsu NanoZoomer (Welwyn 
Garden City, Hertfordshire, UK) at x20 magnification and visualized using Slidepath Digital 
Image Hub, version 4.0.1 (Leica Biosystems, UK).  Assessment of tumour-specific 
membrane, cytoplasmic and nuclear ph-FAK Y397, ph-FAK Y861 and ph-FAK Y925 expression 
was performed by two examiners (NMA and FJG) blinded to clinical data at x20 
magnification (total magnification x400) using the weighted histoscore.  The weighted 
histoscore provides an assessment of the percentage and density of staining and is calculated 
as follows: 0x% not stained + 1x% weakly stained + 2x % moderately stained + 3x % 
strongly stained as shown in figure 3 (A, B, C and D).  This gives a range of scores from 0 to 
300.  To ensure reproducibility, 20% of tumours were co-scored by a second investigator; the 
intra-class correlation coefficient for all markers was > 0.70. 
9 
 
Statistical analysis  
Patients were split into low and high expression using the median for all 
phosphorylation sites.  Survival analysis was examined using Kaplan-Meier curves and the 
log-rank test.  The relationships between FAK phosphorylation, molecular subtypes, and the 
tumour microenvironment were examined using the Chi-square test for linear trend.  
Univariate survival analysis was performed using Cox regression survival analysis to assess 
hazard ratios and 95% confidence intervals.  Multivariate survival analysis was performed 
using cox regression survival analysis using a backwards conditional method assessed 
independent prognostic factors along with common clinical and pathological factors.  A P-
value <0.05 was considered statistically significant and the study conformed to the remark 
criteria.  All analysis was performed using SPSS version 24.0 (IBM SPSS IL, USA).  
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RESULTS 
The majority of patients were older than 50 years (71%), had tumours size ≤2 cm (58%), had 
grade II carcinoma (41%), no axillary lymph node involvement (53%), and had low Klintrup–
Mäkinen grade (73%). 
The correlation between tumour-specific ph-FAK Y397, ph-FAK Y861, and ph-FAK Y925 
expression in patients with primary operable ductal breast cancer is presented in Table 1.  
Membranous ph-FAK Y397 expression correlated with cytoplasmic ph-FAK Y397 expression 
(P<0.001), nuclear ph-FAK Y397 expression (P=0.001), membranous ph-FAK Y861 expression 
(P<0.001), cytoplasmic ph-FAK Y861 expression (P<0.001), nuclear ph-FAK Y861 expression 
(P=0.002), and membranous ph-FAK Y925 expression (P<0.001).  Cytoplasmic ph-FAK Y397 
expression correlated with nuclear ph-FAK Y397 expression (P<0.001), membranous ph-FAK 
Y861 expression (P=0.002), cytoplasmic ph-FAK Y861 expression (P<0.001), and nuclear ph-
FAK Y861 expression (P<0.001).  Nuclear ph-FAK Y397 expression correlated with 
cytoplasmic ph-FAK Y861 expression (P=0.002), nuclear ph-FAK Y861 expression (P<0.001), 
membranous ph-FAK Y925 expression (P=0.003), and nuclear ph-FAK Y925 expression 
(P=0.019).  Membranous ph-FAK Y861 expression correlated with cytoplasmic ph-FAK Y861 
expression (P<0.001), nuclear ph-FAK Y861 expression (P=0.001), and membranous ph-FAK 
Y925 expression (P<0.001).  Cytoplasmic ph-FAK Y861 expression correlated with nuclear ph-
FAK Y861 expression (P<0.001).  Nuclear ph-FAK Y861 expression correlated with 
membranous ph-FAK Y925 expression (P=0.001).  Cytoplasmic ph-FAK Y925 expression 
correlated with nuclear ph-FAK Y925 expression (P=0.001).  When assessing the correlation 
coefficients (CC), correlations between cytoplasmic ph-FAK Y397 and both membranous ph-
FAK Y397 expression (CC=0.513) and cytoplasmic ph-FAK Y861 (CC=0.404), and between 
nuclear ph-FAK Y397 and nuclear ph-FAK Y861 (CC=0.439) were considered as significant 
(CC>0.4). 
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The median follow-up for alive patients (n=275) was 150 months with 96 cancer-
specific deaths and 90 non-cancer deaths.  The relationship between tumour-specific ph-FAK 
Y397, ph-FAK Y861, ph-FAK Y925 expression and cancer specific survival (CSS) in the full 
cohort was examined as shown in Table 2 (n=474).  High expression of membranous ph-FAK 
Y397 was associated with reduced CSS (P=0.040) (Figure 1A) with 10-year survival reduced 
from 80% (low expression) to 71% (high expression).  Similarly, high expression of nuclear 
ph-FAK Y397 was associated with reduced CSS (P=0.003) (Figure 1B) with 10-year survival 
reduced from 84% (low expression) to 72% (high expression).  However, high expression of 
cytoplasmic ph-FAK Y925 was associated with increased CSS (P=0.044) (Figure 1C) with 10-
year survival increased from 75% (low expression) to 83% (high expression).  No other 
phosphorylation sites at any cellular location were associated with CSS. 
 The relationship between tumour-specific phosphorylation, molecular subtypes, and 
the tumour microenvironment was assessed.  High expression of membranous ph-FAK Y397 
(n=419; Table 3) was significantly associated with increased tumour grade (P<0.001), 
molecular subtypes (P<0.001), increased tumour necrosis (P<0.001), high Klintrup–Mäkinen 
grade (P<0.001), increased CD138+ plasma cells (P=0.031), and endocrine therapy 
(P=0.001).  Whereas, high expression of nuclear ph-FAK Y397 (n=419, Table 4) was 
associated with decreased age (P=0.042), and increased CD138+ plasma cells (P=0.001).  
However, high expression of cytoplasmic ph-FAK Y925 (n=443; Table 5) was significantly 
associated with decreased tumour grade (P<0.001), no involved lymph node (P=0.020), 
molecular subtypes (P<0.001), decreased tumour necrosis (P<0.001), low Klintrup–Mäkinen 
grade (P<0.001), decreased CD4+ T-cells, decreased CD138+ plasma cells (P=0.034), 
endocrine therapy (P<0.001), and chemotherapy (P=0.048). 
The relationship between FAK phosphorylation, clinicopathological characteristics 
and CSS is presented in Table 6 (n=474).  In univariate analysis, tumour size (P<0.001), 
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tumour grade (P<0.001), involved lymph node (P<0.001), molecular subtypes (P<0.001), 
tumour necrosis (P<0.001), tumour budding (P<0.001), tumour stroma percentage (P<0.001), 
Klintrup–Mäkinen grade (P=0.095), CD8+ T-cells (P=0.004), CD138+ plasma cells 
(P=0.003), blood vessel invasion (P<0.001), lymph vessel invasion (P<0.001), membranous 
ph-FAK Y397 (P=0.042), nuclear ph-FAK Y397 (P=0.003), and cytoplasmic ph-FAK Y925 
(P=0.046) were associated with CSS.  On multivariate analysis, involved lymph node 
(P=0.019), molecular subtypes (P=0.009), tumour necrosis (P<0.001), tumour budding 
(P=0.005), tumour stroma percentage (P=0.007), CD8+ T-cells (P=<0.001), CD138+ plasma 
cells (P=0.019), blood vessel invasion (P=0.002), lymph vessel invasion (P=0.023), and 
nuclear ph-FAK Y397 (P=0.017) were independent prognostic factors.  
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DISCUSSION 
The present study examined the level of phosphorylation of FAK at (tyrosine residue) 
Y397, Y861, and Y925 and assessed their relationship with clinicopathological characteristics, 
the tumour microenvironment and survival in patients with primary operable ductal breast 
cancer.  The study showed a significant correlation between membranous, cytoplasmic and 
nuclear ph-FAK Y397 , membranous, cytoplasmic and nuclear ph-FAK Y861, and membranous 
ph-FAK Y925, suggesting these sites may work together to regulated downstream pathways in 
these patients.  Furthermore, membrane and nuclear ph-FAK Y397 associated with decreased 
survival whereas nuclear ph-FAK Y925 associated with improved survival.  This suggests that 
FAK can differentially effect survival depending on the site of phosphorylation and 
highlights that each site needs to be investigated individually in patients with primary 
operable ductal breast cancer. 
It has previously been shown that phosphorylation of FAK at tyrosine residue 861 
(Y861) is reliant on the auto phosphorylation of FAK at Y397.  Indeed, it has been reported that 
the auto-phosphorylation of FAK at Y 397 allows a conformational change that unmasks the 
binding site for Src kinase which, in turn, facilitates further phosphorylation of FAK at Y 861 
[9].  Similarly, this auto phosphorylation may also lead to the unmasking of the Y925 site 
allowing phosphorylation at this site by ERK.  To confirm this, it would be of interest to 
examine the association between ph-FAK Y397, ph-FAK Y861, and FAK Y925. 
In the present study, a correlation was observed from the scatter plots between 
cytoplasmic ph-FAK Y397 and both membranous ph-FAK Y397 expression (CC=0.513) and 
cytoplasmic ph-FAK Y861 (CC=0.404), and between nuclear ph-FAK Y397 and nuclear ph-
FAK Y861 (CC=0.439).  A correlation coefficient (CC) between (0.40-0.59) may be 
considered to have a moderate correlation as reported in the bmj (Correlation and regression) 
[28]. 
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In the current study, it was observed that high expression of membrane and nuclear ph-
FAK Y397 were associated with outcome in early stage breast cancer.  In addition, high 
expression of membrane ph-FAK Y397 was associated with increased tumour grade, 
molecular subtypes, increased tumour necrosis, low Klintrup–Mäkinen grade, increased 
CD138+ plasma cells, and endocrine therapy, suggesting it is associated with aggressive 
disease.  In addition, high expression of nuclear ph-FAK Y397 was associated with decreased 
age and increased CD138+ plasma cells.  Recently, Dwyer and co-workers have confirmed a 
role for FAK in NF-κB signalling [30] and is associated with severe drop in the immune 
response [31],suggesting that auto-phosphorylation of FAK at Y397 can potentially modulate 
inflammation within the tumour microenvironment in patients with primary operable ductal 
breast cancer[30].  Based on the previous information, this may suggest that both canonical 
and non-canonical pathways are activated and this activation was significantly associated 
with inflammatory characteristics.  However further work is required to substantiate this 
hypothesis. 
In the present study, there was a significant association between membranous and 
nuclear ph-FAKY397which may suggest that FAK moves to the nucleus once activated at 
this site to modulate the pro-tumorigenic inflammatory response.  Interestingly, Lachowski 
and co-workers suggested that Yes-associated protein (YAP) translocates to the nucleus and 
become active under control of FAK [31].  Therefore, inhibiting phosphorylation at this site 
may improve survival in patients with primary operable ductal breast cancer.  However 
further work is required to substantiate this hypothesis. 
Compared with low, high phosphorylation of nuclear ph-FAK Y397 was significantly 
associated with poorer cancer specific survival.  That may be due to nuclear ph-FAK Y397 
promoting P53 degradation in the nucleus [32].  Therefore, overexpression of FAK in human 
tumour cells might contribute to malignancy by promoting survival under conditions that 
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would normally lead to cell death.  Indeed, Golubovskaya and co-workers have reported in a 
cell line study that inhibition FAK phosphorylation at Y397 and Y577 has been shown to have 
synergistic effects with inhibition of EGF-receptor signalling, leading to apoptosis in breast 
cancer cells [33, 34].  More recently, it was reported that in 600 patients with breast cancer, 
the FAK promoter region contains p53 binding sites, and that p53 inhibits FAK transcription 
and regulates its expression in tumour samples.  Furthermore, it was shown that FAK 
overexpression and p53 mutations are directly associated [35].  Therefore, from the present 
work, it is suggested that ph-FAK Y397 would present a rational therapeutic target in patients 
with primary operable ductal breast cancer, which is of particular interest now with many 
inhibitors entering clinical trials [36]. 
The results of the present study also show that high expression of cytoplasmic ph-FAK 
Y925 was significantly associated with decreased tumour grade, molecular subtypes, no 
involved lymph node, decreased tumour necrosis, low Klintrup–Mäkinen grade, decreased 
CD138+ plasma cells, endocrine therapy, chemotherapy, and better cancer specific survival.  
This suggests that cytoplasmic ph-FAK Y925 is not regulating the same downstream pathways 
as ph-FAK Y397.  This is not surprising as this site resides in the C terminal domain and 
provides binding sites for SH2 (Src homology-2) domain-containing proteins, whereas Y397 
resides in the kinase domain [37, 38, 39].  Furthermore, this site is activated by ERK 
signalling pathway, which has previously been shown to be associated with improved 
survival and decreased inflammation suggesting that FAK can differentially regulate the 
inflammatory response depending on the sites phosphorylated [40, 41, 42]. 
The main limitation of the present study was that although there was extensive 
characterization of tumour and host characteristics these observations were cross-sectional in 
nature.  Therefore, the associations observed may not be causal in effect.  In addition, 
although there was 10-year follow-up of the patients, contemporary management of ductal 
breast cancer has changed over this period.  Nevertheless, the present results provide 
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important information pertaining to the importance of the FAK signal transduction pathways 
in the development of aggressive phenotypic characteristics in patients with primary operable 
ductal breast cancer. 
In summary, the results of the present study showed that membranous and nuclear ph-
FAK Y397, and cytoplasmic ph-FAK Y925 were differentially associated with 
clinicopathological characteristic and survival but only nuclear ph-FAK Y397 was an 
independently prognostic factor in patients with primary operable ductal breast cancer.  
Therefore, nuclear ph-FAK Y397 could be a potential target in treatment of patients with 
primary operable ductal breast cancer.  Furthermore, the results suggest it is important to 
know which site is phosphorylated and not just to look at a surrogate of FAK activation when 
assessing patient survival.
17 
 
REFERENCE 
[1] Brenton JD, Carey LA, Ahmed AA, Caldas C.  Molecular classification and 
Molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 
10; 23(29):7350-60. Epub 2005 Sep 6.  Review.  PubMed PMID: 16145060. 
 
 
[2] Sobin LH, Fleming ID. TNM Classification of Malignant Tumours, fifth edition 
(1997).  Union Internationale Contre le Cancer and the American Joint Committee on 
Cancer.Cancer. 1; 80(9):1803-4. PubMed PMID: 9351551. 
 
 
[3] Conklin MW, Keely PJ. Why the stroma matters in breast cancer: insights into breast 
cancer patient outcomes through the examination of stromal biomarkers. Cell Adh Migr. 
2012 May-Jun;6(3):249-60. doi: 10.4161/cam.20567. Epub 2012 May 1. Review. 
PubMed PMID: 22568982; PubMed Central PMCID: PMC3427239. 
 
 
[4] Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, 
Konstantoudakis K, Stamatakos M. Correlation between Ki67 and breast cancer 
prognosis. Oncology. 2013;84(4):219-25. doi: 10.1159/000346475. Epub 2013 Jan 24. 
Review. PubMed PMID: 23364275. 
 
 
[5] Matsumoto H, Koo SL, Dent R, Tan PH, Iqbal J. Role of inflammatory infiltrates in 
triple negative breast cancer. J Clin Pathol. 2015 Jul;68(7):506-10. doi: 
10.1136/jclinpath-2015-202944. Epub 2015 Mar 6. Review. PubMed PMID: 25750267. 
 
 
[6]Mohammed ZM, Going JJ, Edwards J, McMillan DC.  The role of the tumour 
inflammatory cell infiltrate in predicting recurrence and survival in patients with primary 
operable breast cancer. Cancer Treat Rev. 2012 Dec; 38(8):943-55. doi: 
10.1016/j.ctrv.2012.04.011. Epub 2012 May 30. Review. PubMed PMID: 22651904. 
 
[7]Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC.  The relationship 
between lymphocyte subsets and clinico-pathological determinants of survival in patients 
with primary operable invasive ductal breast cancer. Br J Cancer. 2013 Sep 
17;109(6):1676-84. doi: 10.1038/bjc.2013.493. Epub 2013 Aug 27. PubMed PMID: 
23982600; PubMed Central PMCID: PMC3777002. 
 
[8] Gujam FJ, Edwards J, Mohammed ZM, Going JJ, McMillan DC.  The relationship 
between the tumour stroma percentage, clinicopathological characteristics and outcome 
in patients with operable ductal breast cancer. Br J Cancer. Jul 8;111(1):157-65. doi: 
18 
 
10.1038/bjc.2014.279. Epub 2014 May 29. PubMed PMID:  24874480; PubMed Central 
PMCID: PMC4090742. 
 
 
[9] Mitra SK, Hanson DA, Schlaepfer DD.  Focal adhesion kinase: in command and 
control of cell motility. Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68.  Review. PubMed 
PMID: 15688067. 
 
 
[10] Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance 
WG.  Overexpression of the focal adhesion kinase (p125FAK) in invasive human 
tumors. Cancer Res. 1995 Jul 1;55(13):2752-5. PubMed PMID: 7796399. 
 
[11] Oktay MH, Oktay K, Hamele-Bena D, Buyuk A, Koss LG. Focal adhesion kinase as 
amarker of malignant phenotype in breast and cervical carcinomas. Hum Pathol. 
2003Mar;34(3):240-5. PubMed PMID: 12673558. 
 
 
[12] Ji HF, Pang D, Fu SB, Jin Y, Yao L, Qi JP, Bai J. Overexpression of focal adhesion 
kinase correlates with increased lymph node metastasis and poor prognosis in non-small-
cell lung cancer. J Cancer Res Clin Oncol. 2013 Mar;139(3):429-35. doi: 
10.1007/s00432-012-1342-8. Epub 2012 Nov 11. PubMed PMID: 23143646. 
 
 
[13] McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The 
role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 
2005 Jul;5(7):505-15. Review. PubMed PMID: 16069815. 
 
 
[14] Chatzizacharias NA, Kouraklis GP, Theocharis SE. Clinical significance of 
FAKexpression in human neoplasia. Histol Histopathol. 2008 May;23(5):629-50. 
Review.PubMed PMID: 18283648. 
 
 
[15] Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer 
Metastasis Rev. 2009 Jun;28(1-2):35-49. doi: 10.1007/s10555-008-9165-4. Review. 
PubMed PMID: 19169797. 
 
 
[16] Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, 
Bonnier P, Garcia S. A signature predictive of disease outcome in breast carcinomas, 
identified by quantitative immunocytochemical assays. Int J Cancer. 2009 May 
1;124(9):2124-34. doi: 10.1002/ijc.24177. PubMed PMID: 19142869. 
 
 
19 
 
[17] Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, 
Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C. 
Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast 
carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol. 2007 
Jul;31(1):49-58. PubMed PMID: 17549404. 
 
 
[18] Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-
Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, 
Gilbert N, Anderton SM, Nibbs RJ, Frame MC. Nuclear FAK controls chemokine 
transcription, Tregs, and evasion of anti-tumor immunity. Cell. 2015 Sep 24;163(1):160-
73. doi: 10.1016/j.cell.2015.09.001. PubMed PMID: 26406376; PubMed Central 
PMCID: PMC4597190. 
 
 
[19] Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. 
Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent 
binding of pp60src. Mol Cell Biol. 1994 Mar;14(3):1680-8. PubMed PMID: 7509446; 
PubMed Central PMCID: PMC358526. 
 
 
[20] Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO. SRC-mediated 
phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to 
survival signaling. Mol Cell Biol. 2004 Sep;24(18):8113-33. PubMed PMID: 15340073; 
PubMed Central PMCID: PMC515031. 
 
 
[21] Lin TH, Aplin AE, Shen Y, Chen Q, Schaller M, Romer L, Aukhil I, Juliano RL. 
Integrin-mediated activation of MAP kinase is independent of FAK: evidence for dual 
integrin signaling pathways in fibroblasts. J Cell Biol. 1997 Mar 24;136(6):1385-95. 
PubMed PMID: 9087451; PubMed Central PMCID: PMC2132513.  
 
[22] Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, 
Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu 
PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, 
Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, 
Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical 
Oncology; College of American Pathologists. American Society of Clinical 
Oncology/College of American Pathologists guideline recommendations for 
immunohistochemical testing of estrogen and progesterone receptors in breast cancer 
(unabridged version). Arch Pathol Lab Med. 2010 Jul;134(7): e48-72. doi: 
10.1043/1543-2165-134.7. e 48. Review. PubMed PMID: 20586616.  
 
 
[23] Mohammed ZM, Going JJ, McMillan DC, Orange C, Mallon E, Doughty JC, 
Edwards J.  Comparison of visual and automated assessment of HER2 status and their 
impact on outcome in primary operable invasive ductal breast cancer. Histopathology. 
2012 Oct;61(4):675-84. doi: 10.1111/j.1365-2559.2012.04280. x. PubMed PMID: 
22747525. 
 
20 
 
 
[24] Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E, 
Doughty JC, Edwards J. Comparison of visual and automated assessment of Ki-67 
proliferative activity and their impact on outcome in primary operable invasive ductal 
breast cancer. Br J Cancer. 2012 Jan 17;106(2):383-8. doi: 10.1038/bjc.2011.569. Epub 
2012 Jan 3. PubMed PMID: 22251968; PubMed Central PMCID: PMC326167. 
 
 
[25]Gujam FJ, Going JJ, Mohammed ZM, Orange C, Edwards J, McMillan DC. 
Immunohistochemical detection improves the prognostic value of lymphatic and blood 
vessel invasion in primary ductal breast cancer. BMC Cancer. Sep 18; 14:676. doi: 
10.1186/1471-2407-14-676. PubMed PMID: 25234410; PubMed Central PMCID: 
PMC4177173. 
 
 
[26] Klintrup K, Mäkinen JM, Kauppila S, Väre PO, Melkko J, Tuominen H, 
Tuppurainen K, Mäkelä J, Karttunen TJ, Mäkinen MJ (2005). Inflammation and 
prognosis in colorectal cancer. Eur J Cancer.41(17):2645-54. Epub 18. PubMed 
PMID:16239109. 
 
 
[27] Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship 
between tumour budding, the tumour microenvironment and survival in patients with 
invasive ductal breast cancer. Br J Cancer. Sep 29;113(7):1066-74. 
doi:10.1038/bjc.2015.287. Epub 2015 Aug 11. PubMed PMID: 26263482. 
 
 
[28] The bmj.  11. Correlation and regression at  https://www.bmj.com/about-
bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression 
 
 
[29]  
 
 
[30]  
 
 
[31] Lachowski D, Cortes E, Robinson B, Rice A, Rombouts K, Del Río Hernández 
AE. FAK controls the mechanical activation of YAP, a transcriptional regulator 
required for durotaxis. FASEB J. 2018 Feb;32(2):1099-1107. doi: 
10.1096/fj.201700721R. Epub 2018 Jan 3. PubMed PMID: 29070586. 
 
 
[32] Lim ST. Nuclear FAK: a new mode of gene regulation from cellular adhesions. Mol 
Cells. 2013 Jul;36(1):1-6. doi: 10.1007/s10059-013-0139-1. Epub 2013 May 16. Review. 
PubMed PMID: 23686429; PubMed Central PMCID: PMC3887928. 
 
 
[33] Golubovskaya V, Beviglia L, Xu LH, Earp HS 3rd, Craven R, Cance W. Dual 
inhibition of focal adhesion kinase and epidermal growth factor receptor pathways 
21 
 
cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J 
Biol Chem. 2002 Oct 11;277(41):38978-87. Epub 2002 Aug 7. PubMed PMID: 
12167618. 
 
 
[34] Beviglia L, Golubovskaya V, Xu L, Yang X, Craven RJ, Cance WG. Focal 
adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment 
and apoptosis. Biochem J. 2003 Jul 1;373(Pt 1):201-10. PubMed PMID: 12659633; 
PubMed  Central PMCID: PMC1223465. 
 
 
[35] Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction 
pathways in cancer. Front Biosci (Landmark Ed). 2010 Jun 1;15:901-12. Review. 
PubMed PMID: 20515733; PubMed Central PMCID: PMC3136041. 
 
 
[36] Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical 
trials. Front Biosci (Landmark Ed). 2014 Jan 1;19:687-706. Review. PubMed PMID: 
24389213; PubMed Central PMCID: PMC3952878. 
 
 
[37] Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion 
kinase at sites in the catalytic domain regulates kinase activity: a role for Src 
family kinases. Mol Cell Biol. 1995 Feb;15(2):954-63. PubMed PMID: 7529876; 
PubMed Central PMCID: PMC231984. 
 
 
[38] Ilić D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. 
Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-
mediated apoptosis. J Cell Biol. 1998 Oct 19;143(2):547-60. PubMed PMID: 9786962; 
PubMed Central PMCID: PMC2132850. 
 
 
[39] Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in 
cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2015  
Feb;63(2):114-28. doi: 10.1369/0022155414561498. Epub 2014 Nov 7. Review. 
PubMed  
PMID: 25380750; PubMed Central PMCID: PMC4305513. 
 
 
[40] Hayashida T, Wu MH, Pierce A, Poncelet AC, Varga J, Schnaper HW. MAP-
kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen 
expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. J 
Cell Sci. 2007 Dec 1;120(Pt 23):4230-40. PubMed PMID: 18032789. 
 
 
[41] Roseweir AK, Halcrow ES, Chichilo S, Powell AG, McMillan DC, Horgan PG, 
Edwards J. ERK and p38MAPK combine to improve survival in patients with BRAF 
mutant colorectal cancer. Br J Cancer. 2018 Aug;119(3):323-329. doi: 
10.1038/s41416-018-0174-y. Epub 2018 Jul 10. PubMed PMID: 29988110. 
22 
 
 
 
[42] Roseweir AK, Bennett L, Dickson A, Cheng K, Quintayo MA, Bayani J, 
McMillan DC, Horgan PG, van de Velde CJH, Seynaeve C, Hasenburg A, Kieback 
DG, Markopoulos C, Dirix LY, Rea DW, Mallon EA, Bartlett JMS, Edwards J. 
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and 
Exemestane Adjuvant Multinational (TEAM) Trial. J Natl Cancer Inst. 2018 Jun 
1;110(6):616-627. doi: 10.1093/jnci/djx255. PubMed PMID: 29917140. 
 
 
[A] Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat 
Rev Immunol. 2017 Sep;17(9):545-558. doi: 10.1038/nri.2017.52. Epub 2017 Jun 5. 
Review. PubMed PMID: 28580957; PubMed Central PMCID: PMC5753586. 
 
 
[B] Dwyer SF, Gao L, Gelman IH. Identification of novel focal adhesion kinase 
substrates: role for FAK in NFκB signaling. Int J Biol Sci. 2015 Feb 
17;11(4):404-10. doi: 10.7150/ijbs.10273. eCollection 2015. PubMed PMID: 
25798060; PubMed Central PMCID: PMC4366639. 
 
 
 
23 
 
Table 1.  The relationship between tumour ph-FAK Y397, ph-FAK Y861, and ph-FAK Y925 expression in patients with primary operable 
ductal breast cancer. 
 Ph-FAK Y397 
cytoplasmic 
expression 
Ph-FAK Y397   
nuclear 
expression 
Ph-FAK Y861 
 membranous 
expression 
Ph-FAK Y861  
cytoplasmic 
expression  
Ph-FAK Y861  
 nuclear 
expression 
Ph-FAK Y925 
membranous 
expression 
Ph-FAK Y925 
cytoplasmic 
expression  
Ph-FAK Y925 
 nuclear 
expression 
Ph-FAK Y397  
membranous 
expression 
0.513** 
<0.001 
0.156** 
0.001 
0.337** 
<0.001 
0.308** 
<0.001 
0.152** 
0.002 
0.232** 
<0.001 
-0.077 
0.126 
-0.007 
0.883 
Ph-FAK Y397  
cytoplasmic 
expression 
 0.249** 
<0.001 
0.157** 
0.002 
0.404** 
<0.001 
0.215** 
<0.001 
0.098 
0.051 
-0.014 
0.781 
0.037 
0.459 
Ph-FAK Y397  
 nuclear  
expression 
  0.047 
0.344 
0.151** 
0.002 
0.439** 
<0.001 
0.149** 
0.003 
0.005 
0.914 
0.118* 
0.019 
Ph-FAK Y861 
 membranous 
expression 
   0.392** 
<0.001 
0.163** 
0.001 
0.249** 
<0.001 
0.055 
0.271 
-0.043 
0.386 
Ph-FAK Y861 
 cytoplasmic 
expression  
    0.380** 
<0.001 
0.076 
0.127 
0.051 
0.305 
-0.080 
0.108 
 
Ph-FAK Y861  
 nuclear  
expression 
     0.171** 
0.001 
0.092 
0.069 
0.075 
0.136 
Ph-FAK Y925 
membranous 
expression 
      -0.036 
0.448 
0.010 
0.827 
Ph-FAK Y925  
cytoplasmic 
expression 
       0.158** 
0.001 
**. Correlation is significant at the 0.01 level (2-tailed) 
*. Correlation is significant at the 0.05 level (2-tailed)  
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Table 2.  The relationship between FAKs phosphorylation and survival in patients with primary operable ductal breast cancer (n=474). 
 Membrane Cytoplasmic Nuclear 
  No 10 yrs. 
CCS 
P-value No 10 yrs. 
CCS 
P-value No 10 yrs. 
CCS 
P-value 
ph-FAK Y397  
Low expression 
High expression 
 
322 
97 
 
80% 
71% 
0.040  
213 
206 
 
77% 
79% 
0.448  
206 
12 
 
84% 
72% 
0.003 
ph-FAK Y861  
Low expression 
High expression 
 
323 
103 
 
80% 
71% 
0.151  
214 
212 
 
80% 
76% 
0.623  
208 
208 
 
81% 
74% 
0.255 
ph-FAK Y925  
Low expression 
High expression 
 
359 
85 
 
81% 
70% 
0.139  
239 
204 
 
75% 
83% 
0.044  
415 
29 
 
78% 
93% 
0.109 
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Table 3.  The relationship between membranous ph-FAK Y397 expression, molecular subtypes, tumour microenvironment and survival 
in patients with primary operable ductal breast cancer (n=419). 
All patients (n=419) Patients Low phosphorylation 
(n=322) 
High phosphorylation  
(n=97) 
P-value 
Age ≤50/>50 years/ missed 128/291/0 99/223 29/68 0.874 
Tumour size (≤2, 2.1-5, >5)/ / missed 240/168/11/0 196/115/11 44/53/0 0.057 
Tumour grade (I/ II/ III)/ missed 75/164/180/0 67/133/122 8/31/58 <0.001 
Involved lymph node (negative/positive)/ missed 223/191/5 170/147 53/44 0.861 
Molecular subtypes (A, B, TN, HER-2)/ missed 194/102/73/30/12 161/80/49/13 33/22/24/17 <0.001 
Tumour necrosis (low/high)/ missed 188/231/0 164/158 24/73 <0.001 
Tumour budding (low/high)/ missed 268/151/0 205/117 63/34 0.818 
Tumour stroma percentage (low/high)/ missed 277/142/0 211/111 66/31 0.647 
Klintrup–Mäkinen grade (low/high)/ missed 298/121/0 244/78 54/43 <0.001 
CD4+ (low/moderate/high)/ missed 177/86/148/8 136/67/112 41/19/36 0.816 
CD8+ (low/moderate/high)/ missed 126/141/144/8 96/114/105 30/27/39 0.490 
CD68+ (low/moderate/high)/ missed 118/145/147/9 85/114/116 33/31/31 0.203 
CD138+ (low/moderate/high)/ missed 220/55/135/9 175/47/93 45/8/42 0.031 
Blood vessel invasion (yes/no)/ missed 368/51/0 284/38 84/13 0.673 
Lymph vessel invasion (no/yes)/ missed 280/139/0 217/105 63/34 0.655 
Endocrine therapy (no/yes)/ missed 119/294/6 78/238 41/56 0.001 
Chemotherapy (no/yes)/ missed 230/186/3 184/135 46/51 0.076 
Alive/cancer death/non cancer death/ missed 233/89/85/12 182/62/68 51/27/17 0.866 
Cancer specific survival (months)a/ missed 419/0 152 (146-158) 138 (125-151) 0.040 
A means 95% CI   
26 
 
Table 4.  The relationship between nuclear ph-FAK Y397 expression, molecular subtypes, tumour microenvironment and survival in 
patients with primary operable ductal breast cancer (n=419). 
All patients (n=419) Patients Low phosphorylation 
(n=206) 
High phosphorylation  
(n=213) 
P-value 
Age (≤50/>50 years)/ missed 127/291/1 53/153 74/138 0.042 
Tumour size (≤2, 2.1-5, >5)/ missed 231/164/11/13 112\86\8 127\82\3 0.136 
Tumour grade (I/ II/ III)/ missed 75/164/179/1 33/89/84 42/75/95 0.973 
Involved lymph node (negative/positive)/ missed 223/190/6 111/93 112/97 0.867 
Molecular subtypes (A, B, TN, HER-2)/ missed 194/102/72/30/21 98/51/31/15 96/51/41/15 0.495 
Tumour necrosis (low/high)/ missed 188/230/1 98/108 90/122 0.293 
Tumour budding (low/high)/ missed 267/151/1 136/70 131/81 0.369 
Tumour stroma percentage (low/high)/ missed 277/141/1 143/63 134/78 0.180 
Klintrup–Mäkinen grade (low/high)/ missed 298/120/1 154/52 144/68 0.123 
CD4+ (low/moderate/high)/ missed 176/86/148/9 85/52/64 91/34/84 0.418 
CD8+ (low/moderate/high)/ missed 125/141/144/9 57/70/74 68/71/70 0.348 
CD68+ (low/moderate/high)/ missed 117/145/147/10 58/67/76 59/78/71 0.688 
CD138+ (low/moderate/high)/ missed 219/55/135/10 119/34/48 100/21/87 0.001 
Blood vessel invasion (yes/no)/ missed 367/51/1 181/25 186/26 0.968 
Lymph vessel invasion (no/yes)/ missed 279/139/1 135/71 144/68 0.604 
Endocrine therapy (no/yes)/ missed 118/294/7 55/147 63/147 0.534 
Chemotherapy (no/yes)/ missed 230/185/4 113/90 117/95 0.922 
Alive/cancer death/non cancer death/ missed 232/89/85/13 126/32/39 106/57/46 0.356 
Cancer specific survival (months)a/missed 419/0 157 (150-164) 141 (133-149) 0.003 
A means 95% CI  
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Table 5.  The relationship between cytoplasmic FAK Y925 expression, molecular subtypes, tumour microenvironment and survival in 
patients with primary operable ductal breast cancer (n=443). 
All patients (n=443) Patients Low phosphorylation 
(n=239) 
High phosphorylation  
(n=204) 
P-value 
Age (≤50/>50 years)/ missed 126/317/0 68/171 58\146 0.996 
Tumour size (≤2, 2.1-5, >5)/ missed 258/172/13/0 134/98/7 124\74\6 0.373 
Tumour grade (I/ II/ III)/ missed 85/180/178/0 37/83/119 48/97/59 <0.001 
Involved lymph node (negative/positive)/ 
missed 235/203/5 114/121 121/82 0.020 
Molecular subtypes (A,B, TN, HER-2)/ missed 213/109/71/28/22 101/48/57/20 112/61/14/8 <0.001 
Tumour necrosis (low/high)/ missed 209/234/0 91/148 118/86 <0.001 
Tumour budding (low/high)/ missed 287/156/0 160/79 127/77 0.303 
Tumour stroma percentage (low/high)/ missed 295/148/0 161/78 134/70 0.709 
Klintrup–Mäkinen grade (low/high)/ missed 322/121/0 155/84 176/37 <0.001 
CD4+ (low/moderate/high)/ missed 195/89/151/8 93/44/95 102/45/56 0.006 
CD8+ (low/moderate/high)/ missed 139/144/152/8 71/72/89 68/72/63 0.194 
CD68+ (low/moderate/high)/ missed 131/150/152/10 72/76/82 59/74/70 0.891 
CD138+ (low/moderate/high)/ missed 237/55/141/10 115/31/84 122/24/57 0.034 
Blood vessel invasion (yes/no)/ missed 390/53/0 208/31 182/22 0.824 
Lymph vessel invasion (no/yes)/ missed 302/141/0 163/76 139/65 0.989 
Endocrine therapy (no/yes)/ missed 117/318/8 85/150 32/168 <0.001 
Chemotherapy (no/yes)/ missed 250/190/3 125/113 125/77 0.048 
Alive/cancer death/non cancer death/ missed 251/93/86/13 128/59/46 123/34/40 0.590 
Cancer specific survival (months)a /missed 443/0 145(138-153) 156 (149-163) 0.044 
A means 95% CI   
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Table 6.  Multivariate analysis of FAK phosphorylation, clinicopathological characteristics and cancer specific survival in patients with 
primary operable ductal breast cancer (n=474). 
 
 Univariate analysis Multivariate analysis 
All patients (n=474) Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Age (<50/>50 years) 1.22 (0.77-1.91) 0.397   
Tumour size (≤2, 2.1-5, >5) 2.11 (1.49-2.97) <0.001  0.108 
Tumour grade (I/ II/ III) 1.87 (1.38-2.53) <0.001  0.458 
Involved lymph node (negative/positive) 2.76 (1.80-4.23) <0.001 1.85 (1.11-3.10) 0.019 
Molecular subtypes (A, B, TN, HER-2) 1.49 (1.23-1.80) <0.001 1.35 (1.08-1.69) 0.009 
Tumour necrosis (low/high) 4.38 (2.65-8.24) <0.001 3.34 (1.77-2.30) <0.001 
Tumour budding (low/high) 2.53 (1.69-3.79) <0.001 2.00 (1.23-3.24) 0.005 
Tumour-stroma percentage (low/high) 2. 19 (1.46-3.27) <0.001 1.86 (1.18-2.92) 0.007 
Klintrup–Mäkinen grade (low/high) 1.44 (0.94-2.19) 0.095  0.789 
CD4+ (low/moderate/high) 0.96 (0.80-1.25) 0.983   
CD8+ (low/moderate/high) 0.70 (0.54-0.89) 0.004 0.55 (0.40-0.74) <0.001 
CD68+ (low/moderate/high) 0.86 (0.67-1.10) 0.222   
CD138+ (low/moderate/high) 1.38 (1.11-1.72) 0.003 1.37 (1.05-1.79) 0.019 
Blood vessel invasion (no/yes) 3.39 (2.14-5.39) <0.001 2.28 (1.35-3.86) 0.002 
Lymph vessel invasion (no/yes) 4.14 (2.75-6.25) <0.001 1.85 (1.09-3.15) 0.023 
Membranous  Ph-FAK Y 397 1.60 (1.02-2.51) 0.042  0.495 
Nuclear Ph-FAK Y397 1.92 (1.25-2.97) 0.003 1.76 (1.11-2.81) 0.017 
Cytoplasmic Ph-FAK Y925 0.65 (0.43-0.99) 0.046  0.281 
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LEGENDS 
 
Figure 1.  The association between FAK phosphorylation and cancer specific survival in 
patients with primary operable ductal breast cancer. 
(A) Kaplan-Meier survival curve showing association between cancer specific survival and 
membranous ph-FAK Y397. 
(B)  
Kaplan-Meier survival curve showing association between cancer specific survival and 
cytoplasmic ph-FAK Y925. 
 
Figure 2.  Flow chart showing patient inclusion and exclusion criteria for study. 
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